CeriBell NASDAQ: CBLL executives said the company's first-quarter results reflected continued momentum in both new account additions and increased usage among existing hospital customers, while outlining early progress in new clinical areas including neonatal seizure monitoring and delirium.
CeriBell, Inc. (CBLL) Q1 2026 Earnings Call Transcript
CeriBell NASDAQ: CBLL reported first-quarter revenue growth of 29% and raised its full-year outlook, as management cited higher usage of its seizure monitoring system and the company's strongest quarter of net new hospital additions since becoming public.
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 26 | $570 | $511.1 | -$58.9 | -10.33% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 1,500 | $17,235 | $29,435.4 | $12,200.4 | 70.79% |
Point72 Asset Management LP Point72 Asset Management LP | 77,733 | $1.42M | $1.52M | $95,611.48 | 6.71% |
Joseph Castro Nuveen LLC | 54,874 | $1.03M | $1.07M | $42,574.98 | 4.14% |
Bobby Adusumilli SJS Investment Consulting Inc. | 3 | $54.99 | $58.79 | $3.8 | 6.91% |
| Health Care Technology Industry | Healthcare Sector | Xingjuan Chao CEO | NASDAQ (NGS) Exchange | 15678C102 CUSIP |
| US Country | 327 Employees | - Last Dividend | - Last Split | - IPO Date |
CeriBell, Inc. is a forward-thinking company that specializes in the creation of cutting-edge, AI-based point-of-care electroencephalography (EEG) technology, primarily designed for the detection and management of neurological conditions. Originally founded in 2014 under the name Brain Stethoscope, Inc., the company adopted its current name, CeriBell, Inc., in August 2015, marking a significant phase in its commitment to innovation in the medical technology arena. Positioned in Sunnyvale, California, CeriBell has focused its efforts on filling the void within the acute care setting, offering advanced solutions that cater to the previously unmet needs of patients suffering from neurological issues.
The CeriBell System: Developed as a novel, state-of-the-art, point-of-care EEG platform, the CeriBell System is designed to provide quick and efficient monitoring capabilities within acute care settings. This system stands out for its ability to deliver rapid diagnostics, which is crucial for the effective management and treatment of patients with neurological conditions. The incorporation of AI technologies within this platform underscores CeriBell’s commitment to pushing the boundaries of medical technology, aiming to offer smarter and more reliable diagnostic solutions.
EEG Disposable Headbands: As part of its product lineup, CeriBell offers disposable EEG headbands that are specifically engineered for ease of use and efficiency. These headbands are integral to the CeriBell System, ensuring that patients are monitored comfortably without the need for complex or time-consuming setup processes. Their disposable nature also highlights CeriBell’s attention to hygiene and patient safety, eliminating cross-contamination risks and encouraging the adoption of the system in various healthcare settings.
Pocket-Sized Battery-Operated Recorders: CeriBell's innovation streak extends to the development of compact, portable EEG recorders. These pocket-sized devices are battery-operated, emphasizing mobility and ease of use in various settings, including outpatient care or in environments where traditional EEG systems may be impractical. By making EEG technology more accessible and convenient, CeriBell aims to bridge the gap in neurological monitoring and care, enabling timely intervention and better patient outcomes.